Abstract:Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS), with a putative autoimmune origin and complex pathogenesis. Modification of the natural history of MS by reducing relapses and slowing disability accumulation was first attained in the 1990 s with the development of the first-generation disease-modifying therapies. Glatiramer acetate (GA), a copolymer of L-alanine, L-lysine, L-glutamic acid, and L-tyrosine, was discovered due to its ability to suppress the animal model of MS, experimental autoimmune encephalomyelitis. Extensive clinical trials and long-term assessments established the efficacy and the safety of GA. Furthermore, studies of the therapeutic processes induced by GA in animal models and in MS patients indicate that GA affects various levels of the innate and the adaptive immune response, generating deviation from proinflammatory to anti-inflammatory pathways. This includes competition for binding to antigen presenting cells; driving dendritic cells, monocytes, and B-cells toward anti-inflammatory responses; and stimulating T-helper 2 and T-regulatory cells. The immune cells stimulated by GA reach the CNS and secrete in situ anti-inflammatory cytokines alleviating the pathological processes. Furthermore, cumulative findings reveal that in addition to its immunomodulatory effect, GA promotes neuroprotective repair processes such as neurotrophic factors secretion, remyelination, and neurogenesis. This review aims to provide an overview of MS pathology diagnosis and treatment as well as the diverse mechanism of action of GA. Significance Statement Understanding the complex MS immune pathogenesis provided multiple targets for therapeutic intervention, resulting in a plethora of agents, with various mechanisms of action, efficacy, and safety profiles. However, promoting repair beyond the body's limited spontaneous extent is still a major challenge. GA, one of the first approved disease-modifying therapies, induces diverse immunomodulatory effects. Furthermore, GA treatment results in elevated neurotrophic factors secretion, remyelination and neurogenesis, supporting the notion that immunomodulatory treatment can support in situ a growth-promoting and repair environment.

Cd4(+)Cd25(+) Regulatory T Cells Contribute to the Therapeutic Effects of Glatiramer Acetate in Experimental Autoimmune Encephalomyelitis

Do Th2 Cells Mediate the Effects of Glatiramer Acetate in Experimental Autoimmune Encephalomyelitis?

Glatiramer Acetate Ameliorates Experimental Autoimmune Neuritis.

CD4+CD25+ regulatory T cells ex vivo generated from autologous naïve CD4+ T cells suppress EAE progression

Glatiramer Acetate-Reactive T-Lymphocytes Regulate Oligodendrocyte Progenitor Cell Number In Vitro

Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression

Glutamic Acid Decarboxylase-Derived Epitopes with Specific Domains Expand CD4(+)CD25(+) Regulatory T Cells.

Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.

Therapeutic role of interferon-γ in experimental autoimmune encephalomyelitis is mediated through a tolerogenic subset of splenic CD11b+ myeloid cells

Effect of glucocorticoid on CD4~+CD25~+ regulatory T cells in mice with experimental autoimmune encephalomyelitis

Cooperation of Invariant NKT Cells and CD4+CD25+ T Regulatory Cells in the Prevention of Autoimmune Myasthenia

Γ-Aminobutyric Acid Transpoter 1 Negatively Regulates T Cell-Mediated Immune Responses and Ameliorates Autoimmune Inflammation in the CNS

Cross-Linking of Gm1 Ganglioside by Galectin-1 Mediates Regulatory T Cell Activity Involving Trpc5 Channel Activation: Possible Role in Suppressing Experimental Autoimmune Encephalomyelitis

Γδ T Cell Subsets Play Opposing Roles in Regulating Experimental Autoimmune Encephalomyelitis.

Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis

Galectin-1 Plays an Essential Role in Intravenous Tolerance in Experimental Autoimmune Encephalomyelitis (BA4P.139)

Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis

Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis

Targeting Ganglioside Epitope 3G11 on the Surface of CD4+ T Cells Suppresses EAE by Altering the Treg/Th17 Cell Balance.